The risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease. MHRA recommended the use of Molnupiravir as soon as possible following a positive COVID-19 test and within five days of symptoms onset.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3k8qJdD
via IFTTT
0 comments:
Post a Comment